Verinders Sidhu News Today

Investigators of this study found similar 90-day mortality rates for patients who underwent total joint arthroplasty with either aspirin or enoxaparin for venous thromboembolism prophylaxis. Verinder S. Sidhu, MS, and colleagues performed a secondary analysis of the CRISTAL cluster randomized trial to analyze 90-day mortality rates among 14,156 patients who received aspirin and 9,302

Trial shows enoxaparin superiority as sole prophylaxis, but based largely on below-the-knee DVT